Pot times July 15, 2005
Purdue Pharma Is Ordered To Suspend New Painkiller
URL: http://www.mapinc.org/drugnews/v05/n1113/a01.htmlNewshawk: chip
Pubdate: Thu, 14 Jul 2005 PURDUE PHARMA IS ORDERED TO SUSPEND NEW PAINKILLER
Source: Wall Street Journal (US)
Section: Pg D3
Copyright: 2005 Dow Jones & Company, Inc.
Contact:
wsj.ltrs@wsj.com
Website: http://www.wsj.com/
Details: http://www.mapinc.org/media/487
Author: Anna Wilde Mathews and Jennifer Corbett Dooren
Bookmark: http://www.mapinc.org/find?232
(Chronic Pain)
Bookmark: http://www.mapinc.org/oxycontin.htm
(Oxycontin/Oxycodone)
Purdue Pharma LP agreed to pull its powerful new painkiller Palladone from the
market because of evidence that, when taken with alcohol, it could cause serious
and sometimes fatal reactions.
The Food and Drug Administration, which asked Purdue Pharma to suspend sales of
the drug, said it hadn't received reports of major problems since the drug went
on the U.S. market in February. The FDA said data from a Purdue
Pharma study showed that, when Palladone capsules were combined with even a
relatively small amount of alcohol, the mechanism ensuring the drug is released
gradually over 24 hours could be disabled.
As a result, patients could get the full effects of Palladone's active
ingredient, the potent narcotic hydromorphone, all at once, leading to problems
including depressed or stopped breathing, coma or death. Even for the
lowest marketed dose of the drug, the FDA said, it could prove fatal.
The agency said a Purdue Pharma study in 24 healthy men showed that with a low
dose of Palladone, concentrations of hydromorphone in the blood could be 5.5
times higher when it was taken with eight ounces of a 40%-alcohol solution.
The move is the latest in a series of recent actions by the agency pressing a
tough line on drug safety matters. Palladone held "no unique benefit
other than its convenience," and the FDA believed that a label warning
wouldn't eliminate the risk that the drug might be taken with alcohol, said
Robert Meyer, an FDA office director. Palladone already had a strong label
warning against the use of alcohol.
The agency also said it planned to review other drugs with time-release
mechanisms -- beginning with other painkillers, but also including other drugs
-- to determine whether there could be similar problems when they interact with
alcohol. Purdue Pharma said about 11,500 patients had been prescribed
Palladone, which was being rolled out gradually in the U.S. market to
reduce the risk of abuse, but a sales figure wasn't immediately available.
For closely held Purdue Pharma, the suspension is a serious blow. The
company counted on Palladone to replace its blockbuster drug OxyContin, which
faces generic competition. OxyContin, also a painkiller, was widely abused
by people who deliberately disabled its time-release structure to get a high.
The company said it might try to bring Palladone back for use in restricted
settings, such as hospitals, and also was working to reformulate it to eliminate
the problem with alcohol.
A spokesman for Purdue Pharma said the FDA's call for a market suspension was
"unanticipated," but the company "complied with their
request." Purdue Pharma submitted data to the agency from human tests with
alcohol last November, before the drug went on the market, and believed the
label warnings "would be sufficient," the spokesman said. The
company said it submitted new data to the FDA in June from a later test, but it
was told this wasn't the basis for the suspension request. The tests were
done voluntarily as part of Purdue Pharma's efforts to pinpoint ways the drug
might be abused.
The FDA's Dr. Meyer said the data from human tests with alcohol that the
agency received before Palladone went on the market were preliminary. The
FDA got final results later and wanted to take action before the drug was widely
available, he said. Though lab tests had shown there was a potential for
Palladone's time-release to be disabled when exposed to alcohol, he said, the
agency was surprised at the serious side effects when people took both the drug
and alcohol.
---- Gary Fields contributed to this article. -
